Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer

Running, not enrolling · Phase 1/Phase 2

Conditions studied: Prostate Cancer Metastatic

In brief

The purpose of this first-in-man study is to evaluate safety and tolerability of ODM-208 in patients with metastatic castration-resistant prostate cancer.

Key facts

Study ID: NCT03436485
Run by: Orion Corporation, Orion Pharma
People needed: 204
Starts: 2018-03-19
Expected to finish: 2026-07-31
Last updated by the study team: 2025-07-22

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

University of Maryland Marlene and Stewart Greenebaum Cancer Center — Baltimore, Maryland, United States
Masonic Cancer Center, University of Minnesota — Minneapolis, Minnesota, United States
Nebraska Cancer Specialists — Omaha, Nebraska, United States
University at Buffalo, Kaleida Health Great Lakes Cancer Care Collaborative — Buffalo, New York, United States
Helsinki University Central Hospital — Helsinki, Finland
Tampere University Hospital — Tampere, Finland
Institute Bergonié — Bordeaux, France
Centre Léon Bérard — Lyon, France
Institute Paoli-Calmettes — Marseille, France
Institut de cancérologie Strasbourg Europe — Strasbourg, France
Hopital Foch — Suresnes, France
Institut Gustave Roussy — Villejuif, France
The Rutherford Cancer Centre, North East — Bedlington, United Kingdom
Velindre Cancer Centre — Cardiff, United Kingdom
The Beatson West of Scotland Cancer Centre — Glasgow, United Kingdom
The Rutherford Cancer Centre, North West — Liverpool, United Kingdom
Royal Marsden Hospital — London, United Kingdom
Charing Cross Hospital — London, United Kingdom
The Christie NHS Foundation Trust — Manchester, United Kingdom
Royal Preston Hospital — Preston, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.